17 July 2019
Dear Global Community of NPC Patients, Families, Friends and Supporters,
I am writing to personally share the news that I will be resigning my position as Orphazyme’s Chief Executive Officer effective October 1, 2019.
This is a bittersweet moment; After ten years, I am deeply dedicated to Orphazyme, our team and our development program, especially our work in NPC. This community – and all of you – have been a primary source of personal motivation for me from day one. I am grateful for the opportunity to work with (and learn from) such an exceptionally passionate, committed group of people and am proud of the progress we have made together towards providing a better future for those living with NPC.
Orphazyme looks forward to welcoming Kim Stratton as our next Chief Executive on October 1, 2019. Kim is a senior executive with a solid grasp of rare diseases. She joins Orphazyme from Shire where she was head of the international commercial function across speciality and rare diseases.
Orphazyme has come a long way and with Kim joining our management team I have full faith the company will continue to progress towards our goal of delivering a novel therapeutic option to those living with NPC.
I thank you for sharing the gift of your time, energy and support and look forward to seeing continued growth and progress in the NPC community for years to come.
With my best wishes,
Anders
